about
Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDSZika virus outbreak: an overview of the experimental therapeutics and treatmentAntiviral effect of nitric oxide during Japanese encephalitis virus infectionDegradation of Japanese encephalitis virus by neutrophilsEnzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytesEmerging Zika virus disease: a public health emergency of global concern.Isolation of Desulfovibrio intestinalis sp. nov. from the hindgut' of the lower termite Mastotermes darwiniensis.Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder.Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a.Towards nanomedicines for neuroAIDS.HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND).Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression.Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155.Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder.Latest trends in drugs of abuse - HIV infection and neuroAIDS.Modulation of HIV pathogenesis and T-cell signaling by HIV-1 NefHIV-1 Nef: hacker of the host cell.Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.Association of radiolabeled urogastrone binding with regenerating intestinal mucosa and epidermal growth factor/urogastrone producing organs in rat.Investigation of Neuropathogenesis in HIV-1 Clade B and C Infection Associated with IL-33 and ST2 Regulation.Paromomycin: uptake and resistance in Leishmania donovani.Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder.Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS.An insight into flaviviral budding: a need to know more.Induction of nitric oxide synthase during Japanese encephalitis virus infection: evidence of protective role.Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family.Alteration in plasma glucose levels in Japanese encephalitis patients.Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases.Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS.Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.Complementary and alternative medicine in alliance with conventional medicine for dengue therapeutics and preventionComplementary and alternative medicine in alliance with conventional medicine for influenza therapeutics and preventionCURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASEJapanese encephalitis: a major public-health debacleLatency, persistence and reactivation of Japanese encephalitis virusA Global Perspective on HIV/AIDSInfluenza A(H1N1)pdm09 virus: therapeutics and challengesJapanese Encephalitis: A Persistent ThreatThe Intolerable Burden of Chikungunya: What’s New, What’s Needed?
P50
Q26781397-9C591FA8-9E58-4C52-92EE-23C53306E0A6Q27010830-649650F8-07D6-44BE-84A7-A77233ED5663Q27486643-7AE25317-2720-4C12-8D83-675805C99727Q27486645-19702FB7-F472-4302-9CAE-4F10DD96D266Q27645558-53C8C506-03D1-4B3B-8061-66E51A9FBF88Q30145657-A8CDCC12-80B7-4C7E-ACCF-26F71671FF77Q30578501-D00ABC1A-2FDC-4FB7-A8AA-8E77E08A365CQ33694166-56D8D757-F5AA-4F8C-9D4D-662B972379A7Q34472532-8DC09947-317F-46A5-B9DF-EDE60FF24B97Q34495140-D816988E-DE14-41C0-B9BC-11340AD868EBQ34903986-443CAA02-2FA6-499F-BA9F-F163AACCBBC1Q34984509-A8ABEA98-7337-4970-98B0-A1F896066629Q35082573-32FC86E1-8354-438A-872A-A30AC88AA203Q35996523-A9D1BCBF-71AA-4A32-AC2C-7D3C1031D882Q36790759-0D90226F-DF52-4F93-8352-427E3F02ADB6Q39577894-B21B723B-6F94-41CA-A3B2-D35D5485CB74Q39658813-F8E04B84-91EE-4AB2-9236-4C7173C87D0DQ40060003-85068450-76A9-4B61-B0CA-D16AF52F93E2Q41126940-69D6D3A1-34EF-404D-87D3-CF95907B82A6Q41140334-AF63E832-88A5-48F5-9992-55ABA22697A2Q41855565-F966799B-3DFE-49C8-9495-E5998CF30158Q42972738-25D293BE-5A0E-4828-AD9E-D432388C8913Q42985603-3B50FCBF-B7AD-4508-966A-D796BC1B4F37Q43000480-A1C34946-F473-4D0A-9D2E-84006C0D5C7DQ43032234-89A9BD6F-4BB7-432C-B214-08421B97C98EQ43882484-045C944B-3EBC-40B9-87EB-5E85ECFEFCA2Q44024343-8F963323-71AA-4B7B-85A5-493AF70B2DD3Q45865173-7C8223AF-58D8-4878-9329-B9AC135EB4F5Q54217247-E96746E7-AC19-4E4A-B306-677479622F94Q54590133-9A76CF4F-5C78-48BA-8B4B-5369E7C3FB3CQ54707080-600BA86E-8A0D-4B0F-9D6F-9ADE73EA1DE2Q56748346-C6AC0BBD-6A8B-440D-B59E-FD7321349633Q56748544-D47922B2-0FFB-4B52-BF14-2E5A7F6A35A7Q56749072-64C9C35D-8D20-4FAF-95ED-32A85FB105B8Q56749174-BD547F73-E175-4273-A2F9-F8E53B5FB52FQ56749405-A24212AD-7EC8-49FE-80F9-432C404F2A18Q56749469-49BF205F-1482-4964-9A32-C47EDF8C9075Q56749511-8AAFBF3F-0464-4EE6-B523-1111A7F647E9Q56749528-F478D1A5-05EF-4272-85F9-029FB78CE04FQ56749560-5F6E3731-3749-4C04-8673-1483351A282B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shailendra K Saxena
@nl
Shailendra K Saxena
@sl
Shailendra K. Saxena
@en
Shailendra K. Saxena
@es
type
label
Shailendra K Saxena
@nl
Shailendra K Saxena
@sl
Shailendra K. Saxena
@en
Shailendra K. Saxena
@es
prefLabel
Shailendra K Saxena
@nl
Shailendra K Saxena
@sl
Shailendra K. Saxena
@en
Shailendra K. Saxena
@es
P214
P244
P106
P1153
7402626270
P214
P244
P31
P496
0000-0003-2856-4185
P734
P7859
lccn-n93802330